Neuroprotective effect of silymarin in 6-hydroxydopamine hemi-parkinsonian rat: Involvement of estrogen receptors and oxidative stress

Neuroscience Letters

Volumn 480, Issue 3, 2010, Pages 206-210

  Baluchnejadmojarad, Tourandokht ^a   Roghani, Mehrdad ^b   Mafakheri, Mehdi ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHED UNIVERSITY   (Iran)

Author keywords

6 Hydroxydopamine; Estrogen receptor; Oxidative stress; Parkinson's disease; Silymarin

Indexed keywords

APOMORPHINE; ESTROGEN RECEPTOR; FULVESTRANT; OXIDOPAMINE; SILYMARIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; ATTENUATION; CIRCLING BEHAVIOR; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL MODEL; EXPERIMENTAL RAT; MALE; NERVE CELL; NEUROPROTECTION; NISSL STAINING; NONHUMAN; OXIDATIVE STRESS; PARKINSONISM; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

ANIMALS; DISEASE MODELS, ANIMAL; MALE; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARKINSONIAN DISORDERS; RATS; RATS, WISTAR; RECEPTORS, ESTROGEN; SILYMARIN;

EID: 77954956439     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.06.038     Document Type: Article

References (36)

1. Baluchnejadmojarad T., Roghani M., Nadoushan M.R.J., Bagheri M. Neuroprotective effect of genistein in 6-hydroxydopamine hemi-parkinsonian rat model. Phytother. Res. 2009, 23:132-135.
2. Bradford M.M. A refined and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
3. Chen S., Le W. Neuroprotective therapy in Parkinson disease. Am. J. Therap. 2006, 13:445-457.
4. Chrungoo V.J., Singh K., Singh J. Silymarin mediated differential modulation of toxicity induced by carbon tetrachloride, paracetamol and d-galactosamine in freshly isolated rat hepatocytes. Indian J Exp. Biol. 1997, 3:611-617.
5. Cyr M., Calon F., Morissette M., Di Paolo T. Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease. J. Psychiatry Neurosci. 2002, 27:12-27.
6. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
7. De Girolamo L., Hargreaves A.J., Billett E.E. Protection from MPTP-induced neurotoxicity in differentiating mouse N2a neuroblastoma cells. J. Neurochem. 2001, 76:650-660.
8. Dehmlow C., Murawski N., de Groot H. Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells. Life Sci. 1996, 58:1591-1600.
9. Dluzen D. Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine. Brain Res. 1997, 767:340-344.
10. El-Shitany N.A., Hegazy S., El-Desoky K. Evidences for antiosteoporotic and selective estrogen receptor modulator activity of silymarin compared with ethinylestradiol in ovariectomized rats. Phytomedicine 2010, 17:116-125.
11. Foley P., Riederer P. Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson's disease. J. Neurol. 2000, 247:82-94.
12. Green P.S., Gridley K.E., Simpkins J.W. Estradiol protects against beta-amyloid (25-35)-induced toxicity in SK-N-SH human neuroblastoma cells. Neurosci. Lett. 1996, 218:165-168.
13. Hu L.F., Lu M., Tiong C.X., Dawe G.S., Hu G., Bian J.S. Neuroprotective effects of hydrogen sulfide on Parkinson's disease rat models. Aging Cell 2010, 9:135-146.
14. Karimi G., Ramezani M., Tahoonian Z. Cisplatin nephrotoxicity and protection by milk thistle extract in rats. Evid. Based Complem. Alternat. Med. 2005, 2:383-386.
15. Lotharius J., Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat. Rev. Neurosci. 2002, 3:932-942.
16. Mazzio E.A., Harris N., Soliman K.F. Food constituents attenuate monoamine oxidase activity and peroxide levels in C6 astrocyte cells. Planta Med. 1998, 64:603-606.
17. Montvale N.J. PDR for Herbal Medicines 2000, Medical Economics Company, pp. 516-520.
18. Nencini C., Giorgi G., Micheli L. Protective effect of silymarin on oxidative stress in rat brain. Phytomedicine 2007, 14:129-135.
19. Nobre H.V., Cunha G.M., de Vasconcelos L.M., Magalhães H.I., Oliveira Neto R.N., Maia F.D., de Moraes M.O., Leal L.K., Viana G.S. Caffeine and CSC, adenosine A2A antagonists, offer neuroprotection against 6-OHDA-induced neurotoxicity in rat mesencephalic cells. Neurochem. Int. 2010, 56:51-58.
20. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1986, Academic Press, San Diego. 2nd ed.
21. Pepping J. Milk thistle: Silybum marianum. Am. J. Health Syst. Pharm. 1999, 56:1195-1197.
22. Roghani M., Baluchnejadmojarad T. Chronic epigallocatechin-gallate improves aortic reactivity of diabetic rats: underlying mechanisms. Vascular Pharmacol. 2009, 51:84-89.
23. Roghani M., Behzadi G. Neuroprotective effect of vitamin E on the early model of Parkinson's disease in rat: behavioral and histochemical evidence. Brain Res. 2001, 892:211-217.
24. Sauer H., Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 1994, 59:401-405.
25. Schwarting R.K.W., Huston J.P. The unilateral 6-hydroxydopamine lesion model in behavioral brain research: analysis of functional deficits, recovery and treatments. Prog. Neurobiol. 1996, 50:275-331.
26. Seidlová-Wuttke D., Becker T., Christoffel V., Jarry H., Wuttke W. Silymarin is a selective estrogen receptor beta (ERbeta) agonist and has estrogenic effects in the metaphysis of the femur but no or antiestrogenic effects in the uterus of ovariectomized (ovx) rats. J. Steroid Biochem. Mol. Biol. 2003, 86:179-188.
27. Shapiro R.M., Glick S.D., Camarota N.A. A two-population model of rat rotational behavior: effects of unilateral nigrostriatal 6-hydroxydopamine on striatal neurochemistry and amphetamine-induced rotation. Brain Res. 1987, 426:323-331.
28. Singh M., Dykens J.A., Simpkins J.W. Novel mechanisms for estrogen-induced neuroprotection. Exp. Biol. Med. 2006, 231:514-521.
29. Sonnenbichler J., Zetl I. Specific binding of a flavonolignane derivative to an estradiol receptor. Prog. Clin. Biol. Res. 1988, 280:369-374.
30. Sonnenbichler J., Scalera F., Sonnenbichler I., Weyhenmeyer R. Stimulatory effects of silibinin and silychristin form the milk thistle Silybum marianum on kidney cells. J. Pharmacol. Exp. Ther. 1999, 290:1375-1383.
31. Soto C., Recoba R., Barrón H., Alvarez C., Favari L. Silymarin increases antioxidant enzymes in alloxan-induced diabetes in rat pancreas. Comp. Biochem. Physiol. Toxicol. Pharmacol. 2003, 136:205-212.
32. Tejada S., Sureda A., Roca C., Gamundí A., Esteban S. Antioxidant response and oxidative damage in brain cortex after high dose of pilocarpine. Brain Res. Bull. 2007, 71:372-375.
33. Velussi M., Cernigoi A.M., De Monte A., Dapas F., Caffau C., Zilli M. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J. Hepatol. 1997, 26:871-879.
34. Von Bohlen und Halbach O., Schober A., Krieglstein K. Genes, proteins, and neurotoxins involved in Parkinson's disease. Progr. Neurobiol. 2004, 73:151-177.
35. Wang M.J., Lin W.W., Chen H.L., Chang Y.H., Ou H.C., Kuo J.S., Hong J.S., Jeng K.C. Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation. Eur. J. Neurosci. 2002, 16:2103-2112.
36. Wu S.S., Frucht S.J. Treatment of Parkinson's disease: what's on the horizon. CNS Drugs 2005, 19:723-743.